دورية أكاديمية
Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use.
| العنوان: | Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use. |
|---|---|
| المؤلفون: | Yildirim I; Department of Pediatrics, Section of Infectious Diseases and Global Health, Yale University School of Medicine, New Haven, Connecticut.; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut.; Yale Institute for Global Health, Yale University, New Haven; Connecticut.; Yale Center for Infection and Immunity, Yale University, New Haven, Connecticut., Lapidot R; Division of Pediatric Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.; Department of Pediatrics, Section of Infectious Diseases, Boston University, Chobanian and Averdisian School of Medicine, Boston, Massachusetts., Shaik-Dasthagirisaheb YB; Department of Pediatrics, Section of Infectious Diseases, Boston University, Chobanian and Averdisian School of Medicine, Boston, Massachusetts., Hinderstein S; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut., Lee H; Department of Pediatrics, Section of Infectious Diseases and Global Health, Yale University School of Medicine, New Haven, Connecticut., Klevens M; Massachusetts Department of Public Health, Boston, Massachusetts., Grant L; Pfizer Inc., New York, New York., Arguedas Mohs AG; Pfizer Inc., New York, New York., Cane A; Pfizer Inc., New York, New York., Madoff L; Massachusetts Department of Public Health, Boston, Massachusetts., Johnson H; Massachusetts Department of Public Health, Boston, Massachusetts., Ivanof C; Massachusetts Department of Public Health, Boston, Massachusetts., Burns M; Massachusetts Department of Public Health, Boston, Massachusetts., Pelton S; Department of Pediatrics, Section of Infectious Diseases, Boston University, Chobanian and Averdisian School of Medicine, Boston, Massachusetts. |
| المصدر: | Pediatrics [Pediatrics] 2024 Jan 01; Vol. 153 (1). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Academy of Pediatrics Country of Publication: United States NLM ID: 0376422 Publication Model: Print Cited Medium: Internet ISSN: 1098-4275 (Electronic) Linking ISSN: 00314005 NLM ISO Abbreviation: Pediatrics Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Elk Grove Village Il : American Academy of Pediatrics Original Publication: Springfield, Ill., Thomas. |
| مواضيع طبية MeSH: | Pneumococcal Infections*/epidemiology , Pneumococcal Infections*/prevention & control, Child ; Humans ; Infant ; Vaccines, Conjugate ; Heptavalent Pneumococcal Conjugate Vaccine/therapeutic use ; Streptococcus pneumoniae ; Pneumococcal Vaccines ; Serogroup ; Incidence |
| مستخلص: | Objectives: We sought to describe the evolving epidemiology of invasive pneumococcal disease (IPD) among children in Massachusetts, United States, over the last 2 decades during which sequential 7-valent pneumococcal conjugate vaccines (PCV7) and 13-valent PCVs (PCV13) were implemented. Methods: Cases of IPD in children aged <18 years were detected between 2002 and 2021 through an enhanced population-based, statewide surveillance system. Streptococcus pneumoniae isolates from normally sterile sites were serotyped and evaluated for antimicrobial susceptibility. IPD incidence rates and rate ratios with 95% confidence intervals (CIs) were calculated. Results: We identified 1347 IPD cases. Incidence of IPD in children aged <18 years declined 72% over 2 decades between 2002 and 2021 (incidence rate ratios 0.28, 95% CI 0.18-0.45). IPD rates continued to decline after replacement of PCV7 with PCV13 (incidence rate ratios 0.25, 95% CI 0.16-0.39, late PCV7 era [2010] versus late PCV13 era [2021]). During the coronavirus disease 2019 pandemic years, 2020 to 2021, the rate of IPD among children aged <18 years reached 1.6 per 100 000, the lowest incidence observed over the 20 years. In PCV13 era, approximately one-third of the IPD cases in children aged >5 years had at least 1 underlying condition (98, 30.3%). Serotypes 19A and 7F contributed 342 (48.9%) of all cases before implementation of PCV13 (2002-2010). Serotype 3 (31, 8.6%), and non-PCV13 serotypes 15B/C (39, 10.8%), 33F (29, 8.0%), 23B (21, 0.8%), and 35B (17, 4.7%) were responsible for 37.8% of cases in PCV13 era (2011-2021). Penicillin nonsusceptibility continued to decline (9.8% vs 5.3% in pre-/late PCV13 era, P = .003), however has become more common among non-PCV13 serotypes compared with vaccine serotypes (14.8% vs 1.4%, P < .001). Conclusions: Robust ongoing surveillance networks are critical for identifying emerging serotypes and development of next-generation vaccine formulations. (Copyright © 2024 by the American Academy of Pediatrics.) |
| المشرفين على المادة: | 0 (Vaccines, Conjugate) 0 (Heptavalent Pneumococcal Conjugate Vaccine) 0 (Pneumococcal Vaccines) |
| تواريخ الأحداث: | Date Created: 20231213 Date Completed: 20240102 Latest Revision: 20240102 |
| رمز التحديث: | 20240102 |
| DOI: | 10.1542/peds.2023-063039 |
| PMID: | 38087952 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1098-4275 |
|---|---|
| DOI: | 10.1542/peds.2023-063039 |